James Chambers to Urinary Bladder Neoplasms
This is a "connection" page, showing publications James Chambers has written about Urinary Bladder Neoplasms.
Connection Strength
0.624
-
Yokota S, Fujii W, Motegi T, Komori M, Nishi R, Chambers JK, Uchida K, Yonezawa T, Momoi Y, Maeda S. Sorafenib inhibits myeloid-derived suppressor cell infiltration in canine transitional cell carcinoma. Vet Immunol Immunopathol. 2025 Dec; 290:111019.
Score: 0.218
-
Eto S, Saeki K, Yoshitake R, Yoshimoto S, Shinada M, Ikeda N, Kamoto S, Tanaka Y, Kato D, Maeda S, Tsuboi M, Chambers J, Uchida K, Nishimura R, Nakagawa T. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. PLoS One. 2019; 14(6):e0218382.
Score: 0.140
-
Tsuboi M, Sakai K, Maeda S, Chambers JK, Yonezawa T, Matsuki N, Uchida K, Nakayama H. Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder. Vet Pathol. 2019 05; 56(3):369-376.
Score: 0.136
-
Maeda S, Tomiyasu H, Tsuboi M, Inoue A, Ishihara G, Uchikai T, Chambers JK, Uchida K, Yonezawa T, Matsuki N. Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq. BMC Cancer. 2018 04 27; 18(1):472.
Score: 0.130